In Depth 15 Feb 2024 Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug? Learn more about Biogen’s strategic realignment from Aduhelm’s controversy to Leqembi’s promise in Alzheimer’s treatment. February 15, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 14 Feb 2024 The next leap in pet health: longevity drugs for dogs Find out how we could stave off the heartbreak of saying goodbye to our dogs, as three longevity drugs for dogs could soon be approved. February 14, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 12 Feb 2024 RNA editing set to take off: could DNA’s short-lived cousin overcome the limitations of CRISPR gene editing? Find out all about about RNA editing, as two candidates have just managed to reach the clinic for the first time. February 12, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Feb 2024 Biotech job market 2024: what to expect? The past year saw pipeline cuts and downsizing plans strike the biotech industry. Does the biotech job market seem to be looking up this year? February 9, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 9 Feb 2024Biosimilars and what’s new in cell and gene therapies This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health. The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and Advanced Therapies Week. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals and a global manufacturer and […] February 9, 2024 Share WhatsApp Twitter Linkedin Email
In Depth 8 Feb 2024 Could we see a new dawn for hair loss treatments? Discover the latest advances in hair loss treatments, from topical therapies to the the groundbreaking potential of JAK inhibitors. February 8, 2024 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Feb 2024 Fourteen biotech companies spearheading the antibody drug conjugate industry The antibody-drug conjugate market has gained significant traction recently. Discover some of the top ADC companies in the industry. February 8, 2024 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 7 Feb 2024 The biggest private biotech investments in January 2024 Jixing Pharmaceuticals, COUR Pharmaceuticals, and OnCusp Therapeutics bagged the biggest private biotech investments in January 2024. February 7, 2024 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 5 Feb 2024 Future of cancer treatment: what will therapy look like in 2034? From groundbreaking immunotherapies to AI diagnostics and new vaccines, explore the innovations shaping the future of cancer treatment. February 5, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 2 Feb 2024BioSenic showcasing knee osteoarthritis treatment Explore a groundbreaking approach to knee osteoarthritis treatment with BioSenic’s JTA-004. Listen to our podcast to learn more! February 2, 2024 Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2024 Can gene therapy be the key to restoring hearing loss? Explore gene therapy’s success in treating genetic hearing loss as a child regains hearing at the Children’s Hospital of Philadelphia. February 1, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Expert Advice 1 Feb 2024 Corporate Sustainability Reporting Directive: Is the life sciences industry ready? 2024 will be the first year when biotechs will have to report on their sustainability data under the CSRD. But is the industry prepared? February 1, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email